322 related articles for article (PubMed ID: 28646887)
1. Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial.
Livingston MH; Mahant S; Ratjen F; Connolly BL; Thorpe K; Mamdani M; Maclusky I; Laberge S; Giglia L; Walton JM; Yang CL; Roberts A; Shawyer AC; Brindle M; Parsons SJ; Stoian CA; Cohen E
Trials; 2017 Jun; 18(1):293. PubMed ID: 28646887
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.
Livingston MH; Mahant S; Connolly B; MacLusky I; Laberge S; Giglia L; Yang C; Roberts A; Shawyer A; Brindle M; Parsons S; Stoian C; Walton JM; Thorpe KE; Chen Y; Zuo F; Mamdani M; Chan C; Loong D; Isaranuwatchai W; Ratjen F; Cohen E
JAMA Pediatr; 2020 Apr; 174(4):332-340. PubMed ID: 32011642
[TBL] [Abstract][Full Text] [Related]
3. A combined intrapleural administration of dornase alfa and tissue plasminogen activator is safe in children with empyema - A pilot study.
Slaats MA; De Dooy J; Van Hoorenbeeck K; Van Schil PEY; Verhulst SL; Hendriks JMH
Acta Chir Belg; 2021 Jun; 121(3):184-188. PubMed ID: 31750793
[TBL] [Abstract][Full Text] [Related]
4. Impact of fibrinolytics on the outcome of empyema in South African children.
Zampoli M; Kappos A; Verwey C; Mamathuba R; Zar HJ
S Afr Med J; 2015 Sep; 105(7):549-53. PubMed ID: 26428749
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.
Zhu Z; Hawthorne ML; Guo Y; Drake W; Bilaceroglu S; Misra HL; Light RW
Chest; 2006 Jun; 129(6):1577-83. PubMed ID: 16778278
[TBL] [Abstract][Full Text] [Related]
6. Drainage, fibrinolytics, or surgery: a comparison of treatment options in pediatric empyema.
Gates RL; Hogan M; Weinstein S; Arca MJ
J Pediatr Surg; 2004 Nov; 39(11):1638-42. PubMed ID: 15547825
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of competing strategies for the treatment of pediatric empyema.
Cohen E; Weinstein M; Fisman DN
Pediatrics; 2008 May; 121(5):e1250-7. PubMed ID: 18450867
[TBL] [Abstract][Full Text] [Related]
8. Sequential intrapleural administration of fibrinolytic drugs and dornase alfa for empyema management. Treatment protocol based on its physicochemical stability.
Bastida C; Salazar-Santander C; Soy D; Sánchez D; Díez C; Badia JR
Farm Hosp; 2019 Dec; 44(1):16-19. PubMed ID: 31901057
[TBL] [Abstract][Full Text] [Related]
9. Are some children with empyema at risk for treatment failure with fibrinolytics? A multicenter cohort study.
Livingston MH; Cohen E; Giglia L; Pirrello D; Mistry N; Mahant S; Weinstein M; Connolly B; Himidan S; Bütter A; Walton JM
J Pediatr Surg; 2016 May; 51(5):832-7. PubMed ID: 26964704
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study.
Bouros D; Schiza S; Patsourakis G; Chalkiadakis G; Panagou P; Siafakas NM
Am J Respir Crit Care Med; 1997 Jan; 155(1):291-5. PubMed ID: 9001327
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema.
Thommi G; Nair CK; Aronow WS; Shehan C; Meyers P; McLeay M
Am J Ther; 2007; 14(4):341-5. PubMed ID: 17667208
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Tissue Plasminogen Activator and DNase for Complicated Pleural Effusions Secondary to Abdominal Pathology.
Majid A; Ochoa S; Chatterji S; Fernandez-Bussy S; Kheir F; Rivera E; Cheng G; Folch E
Ann Am Thorac Soc; 2017 Mar; 14(3):342-346. PubMed ID: 28079399
[TBL] [Abstract][Full Text] [Related]
13. Stratifying fibrinolytic dosing in pediatric parapneumonic effusion based on ultrasound grade correlation.
James CA; Braswell LE; Pezeshkmehr AH; Roberson PK; Parks JA; Moore MB
Pediatr Radiol; 2017 Jan; 47(1):89-95. PubMed ID: 27709281
[TBL] [Abstract][Full Text] [Related]
14. Tissue plasminogen activator for the treatment of parapneumonic effusions in pediatric patients.
Israel EN; Blackmer AB
Pharmacotherapy; 2014 May; 34(5):521-32. PubMed ID: 24390857
[TBL] [Abstract][Full Text] [Related]
15. Management of Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and Deoxyribonuclease.
Mehta HJ; Biswas A; Penley AM; Cope J; Barnes M; Jantz MA
Respiration; 2016; 91(2):101-6. PubMed ID: 26761711
[TBL] [Abstract][Full Text] [Related]
16. Cryptococcal empyema treated with tube thoracostomy and intrapleural fibrinolysis.
Kohli A; Sachdeva A; Pickering EM
Monaldi Arch Chest Dis; 2020 Nov; 90(4):. PubMed ID: 33169591
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study.
Stefanutti G; Ghirardo V; Barbato A; Gamba P
Surgery; 2010 Sep; 148(3):589-94. PubMed ID: 20304453
[TBL] [Abstract][Full Text] [Related]
18. Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial.
Kheir F; Thakore S; Mehta H; Jantz M; Parikh M; Chee A; Kaphle U; Sisnega C; Fernandez-Bussy S; Majid A
Ann Am Thorac Soc; 2020 Aug; 17(8):958-964. PubMed ID: 32421353
[No Abstract] [Full Text] [Related]
19. Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project.
Popowicz N; Bintcliffe O; De Fonseka D; Blyth KG; Smith NA; Piccolo F; Martin G; Wong D; Edey A; Maskell N; Lee YCG
Ann Am Thorac Soc; 2017 Jun; 14(6):929-936. PubMed ID: 28324671
[TBL] [Abstract][Full Text] [Related]
20. Medical management of parapneumonic pleural disease.
Barnes NP; Hull J; Thomson AH
Pediatr Pulmonol; 2005 Feb; 39(2):127-34. PubMed ID: 15573391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
